Immatics (IMTX) Beginning Cash Balance (2019 - 2024)
Immatics (IMTX) posted Beginning Cash Balance of $249.0 million for Q1 2025, up 4.93% sequentially from $237.3 million in Q1 2024, and up 4.93% YoY from $237.3 million in Q1 2024.
Analysis
Immatics (IMTX) Beginning Cash Balance (2019 - 2024) Analysis & Trends
Immatics has reported Beginning Cash Balance for 5 years, with the latest figure at $249.0 million in Q1 2025.
- Quarterly Beginning Cash Balance rose 4.93% year-over-year to $249.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $486.4 million (up 25.81% YoY) and the FY2021 annual result came in at $245.6 million, up 108.12% from the prior year.
- Beginning Cash Balance grew to $249.0 million in Q1 2025 per IMTX's latest filing, from $237.3 million in the prior quarter.
- Over five years, Beginning Cash Balance peaked at $250.3 million in Q1 2021 and troughed at $149.3 million in Q1 2022.
- A 4-year average of $221.5 million and a median of $243.2 million in 2024 frame the typical range for Beginning Cash Balance.
- The sharpest annual moves came in 2021 and 2022: Beginning Cash Balance surged 119.4% in 2021, then tumbled 40.37% in 2022.
- Over 4 years, Beginning Cash Balance stood at $250.3 million in 2021, then sank by 40.37% to $149.3 million in 2022, then surged by 59.01% to $237.3 million in 2024, then increased by 4.93% to $249.0 million in 2025.
- According to Business Quant data, Beginning Cash Balance over the past three periods registered $249.0 million, $237.3 million, and $149.3 million for Q1 2025, Q1 2024, and Q1 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 239.93 Mn |
| Dec 31, 2023 | 159.80 Mn |
| Dec 31, 2022 | 135.69 Mn |
| Sep 30, 2022 | 134.09 Mn |
| Jun 30, 2022 | 141.91 Mn |
| Mar 31, 2022 | 149.26 Mn |
| Dec 31, 2021 | 237.41 Mn |
| Sep 30, 2021 | 244.74 Mn |
| Jun 30, 2021 | 249.92 Mn |
| Mar 31, 2021 | 250.33 Mn |
| Dec 31, 2020 | 123.23 Mn |
| Sep 30, 2020 | 120.72 Mn |
| Jun 30, 2020 | 113.84 Mn |
| Mar 31, 2020 | 114.10 Mn |
| Dec 31, 2019 | 43.57 Mn |
| Sep 30, 2019 | 43.80 Mn |
| Jun 30, 2019 | 44.23 Mn |